Retatrutide is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Retatrutide (Retatrutide (LY3437943)) is a Triple hormone receptor agonist researched for substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers. Common dosages range from 4-12 mg weekly (maintenance after titration) administered once weekly. Below are the most frequently asked questions.
Frequently Asked Questions About Retatrutide
What is Retatrutide?
Retatrutide (Retatrutide (LY3437943)) is a Triple hormone receptor agonist. Novel synthetic peptide developed by Eli Lilly targeting GIP, GLP-1, AND glucagon receptors simultaneously. It is researched for substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers.
What is the recommended Retatrutide dosage?
Common dosages range from 4-12 mg weekly (maintenance after titration), administered once weekly via subcutaneous injection. Cycles typically run 48+ weeks (continuous therapy in trials).
What are the side effects of Retatrutide?
Gastrointestinal effects predominate: diarrhea, vomiting, constipation, nausea. Generally manageable and dose-dependent. Potential pancreatitis risk similar to GLP-1 agonists.
Is Retatrutide legal?
Not FDA-approved as of March 2026. NDA filing expected late 2026-early 2027.
What is the half-life of Retatrutide?
The half-life of Retatrutide is approximately 4-5 days, which determines the once weekly dosing schedule.
How do you reconstitute Retatrutide?
Add bacteriostatic water to the lyophilized Retatrutide vial. Let the water run down the side — never spray on the powder. Swirl gently. Use our peptide calculator for exact amounts.
Can you stack Retatrutide with other peptides?
Triple agonism provides inherent synergy — not typically stacked with other GLP-1 or GIP agonists.
Where can you buy Retatrutide?
Retatrutide is available as a research chemical from vetted suppliers with third-party COA testing.
How long does it take Retatrutide to work?
Initial effects may be noticed within 1-2 weeks, with more significant results typically appearing by weeks 4-8 of a 48+ weeks (continuous therapy in trials) cycle.
What makes Retatrutide unique?
The first triple hormone agonist targeting three distinct metabolic pathways simultaneously — producing superior weight loss compared to both semaglutide (single) and tirzepatide (dual) agonists.
Complete Guide
Retatrutide : Benefits, Dosage, Side Effects & Research
Related Reading
- Retatrutide Dosage Guide
- Retatrutide Benefits
- Retatrutide Side Effects
- Retatrutide Stacking Guide
- Retatrutide Cycle Guide
- Retatrutide Research
Calculate Your Retatrutide Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Retatrutide.
Open Calculator →Research-Grade Sourcing
If you're going to research Retatrutide, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Retatrutide?
Retatrutide (Retatrutide (LY3437943)) is a Triple hormone receptor agonist. Novel synthetic peptide developed by Eli Lilly targeting GIP, GLP-1, AND glucagon receptors simultaneously. It is researched for substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers.
What is the recommended Retatrutide dosage?
Common dosages: 4-12 mg weekly (maintenance after titration) administered once weekly via subcutaneous injection. Cycle length: 48+ weeks (continuous therapy in trials). Half-life: approximately 4-5 days. Use our peptide calculator for exact reconstitution math.
What are the side effects of Retatrutide?
Gastrointestinal effects predominate: diarrhea, vomiting, constipation, nausea. Generally manageable and dose-dependent. Potential pancreatitis risk similar to GLP-1 agonists.
Is Retatrutide safe?
Retatrutide has shown a preliminary safety profile in research. Not FDA-approved as of March 2026. NDA filing expected late 2026-early 2027. All research should follow appropriate safety protocols.